Partial germline reversions can increase VRC07 potency and breadth

Partial germline reversions can increase VRC07 potency and breadth

Bibliographic Details
Main Authors:	Rudicell RS, Georgiev I, Yang Z, O'Dell S, Kwon Y, Zhu J, Wu X, Kwong PD, Mascola JR, Nabel GJ
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
by: Nabel GJ, et al.
Published: (2009-10-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
by: Graham T. Holt, et al.
Published: (2023-07-01)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
by: Emilie Seydoux, et al.
Published: (2021-05-01)

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).
by: Mary E Enama, et al.
Published: (2014-01-01)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
by: Andrew J Borst, et al.
Published: (2018-11-01)

Diet Breadth Mediates the Prey Specificity of Venom Potency in Snakes
by: Keith Lyons, et al.
Published: (2020-01-01)

FINAD + VRC = Controllers Instituut
by: G. H. Koolman
Published: (1995-05-01)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
by: Chuang G, et al.
Published: (2012-09-01)

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
by: Ema T Crooks, et al.
Published: (2018-05-01)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
by: Laura Radić, et al.
Published: (2023-04-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
by: Baoshan Zhang, et al.
Published: (2023-12-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
by: Dai K, et al.
Published: (2012-09-01)

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency
by: Nicole Frumento, et al.
Published: (2022-08-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates
by: Foulds K, et al.
Published: (2009-10-01)

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
by: Martina S. Wesley, et al.
Published: (2021-08-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
by: Rebecca T. van Dorsten, et al.
Published: (2021-09-01)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
by: Maria L. Knudsen, et al.
Published: (2022-11-01)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques.
by: Giulia Calenda, et al.
Published: (2019-05-01)

Probing the breadth of macrolide glycosyltransferases: in vitro remodeling of a polyketide antibiotic creates active bacterial uptake and enhances potency.
by: Yang, M, et al.
Published: (2005)

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
by: Manoj S. Nair, et al.
Published: (2023-04-01)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
by: Zhiqiang Ku, et al.
Published: (2022-09-01)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
by: Ku, Zhiqiang, et al.
Published: (2023)

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
by: Shinji Saito, et al.
Published: (2019-01-01)

Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype.
by: Chad D Nix, et al.
Published: (2020-04-01)

P09.07 Determining potency, activation and expansion of antigen specific T cells
by: B Hansen, et al.
Published: (2024-03-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
by: Michelle C Crank, et al.
Published: (2016-01-01)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
by: Mata-Fink, Jordi, et al.
Published: (2013)

The breadth of silence
by: Nur Sadrina Mohamad Shukor
Published: (2017)

The Breadth of the Riches
by: Sydnor Jon Paul
Published: (2016-04-01)

Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort
by: Ying Chen, et al.
Published: (2023-10-01)